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Abstract
Introduction Dicer is a ribonuclease that mediates RNA
interference both at the transcriptional and the post-
transcriptional levels. Human dicer gene expression is regulated
in different tissues. Dicer is responsible for the synthesis of
microRNAs and short temporal (st)RNAs that regulate the
expression of many genes. Thus, understanding the control of
the expression of the dicer gene is essential for the appreciation
of double-stranded (ds)RNA-mediated pathways of gene
expression. Human dicer mRNA has many upstream open
reading frames (uORFs) at the 5'-leader sequences (the
nucleotide sequence between the 5'-end and the start codon of
the major ORF), and we studied whether these elements at the
5'-leader sequences regulate the expression of the dicer gene.
Method We determined the 5'-leader sequences of the dicer
mRNAs in human breast cells by 5'-RACE and S1-nuclease
protection analysis. We have analyzed the functions of the 5'-
leader variants by reporter gene expression in vitro and in vivo.
Results We found that the dicer transcripts in human breast
cells vary in the sequence of their 5'-leader sequences, and that
alternative promoter selection along with alternative splicing of
the 5'-terminal exons apparently generate these variations. The
breast cell has at least two predominant forms of dicer mRNAs,
one of which has an additional 110 nucleotides at the 5'-end.
Sequence comparison revealed that the first 80 nucleotides of
these mRNA isoforms are encoded by a new exon located
approximately 16 kb upstream of the reported start site. There
are 30 extra nucleotides added to the previously reported exon
1. The human breast cells studied predominantly express two 5'-
leader variants of dicer mRNAs, one with the exons 2 and 3
(long form) and the other without them (short form). By reporter
gene expression analysis we found that the exon 2 and 3
sequences at the 5'-leader sequences are greatly inhibitory for
the translation of the mRNA into protein.
Conclusion Dicer gene expression in human breast cells is
regulated by alternative promoter selection to alter the length
and composition of the 5'-leader sequence of its mRNA.
Furthermore, alternative splicing of its exon 2 and 3 sequences
of their pre-mRNA creates a more translationally competent
mRNA in these cells.
Introduction
RNA interference (RNAi), a process of silencing gene expres-
sion, involves the generation of short, double-stranded RNA
(dsRNA) molecules by an enzyme called dicer, which cleaves
RNA duplexes into 21–23 base-pair oligomers [1-8]. These
oligomers are called, depending on their end-point functions,
small interfering RNAs (siRNA), microRNA (miRNA) or short
temporal RNA (stRNA) [9]. These small RNA molecules cause
sequence-specific post-transcriptional gene silencing by guid-
ing an endonuclease, the RNAi-induced silencing complex
(RISC), to mRNA [10,11]. This ubiquitous process has also
been recently reported [12-15] in human cells to induce tran-
scriptional silencing through promoter methylation.
Dicer gene expression is regulated in different tissues in
humans [16]. Because dicer catalyzes the biosynthesis of
miRNAs and stRNAs that in turn regulate the expression of
many genes, it is likely that the expression of the dicer gene
itself is a highly regulated process [9-11]. While studying the
published 5'-leader sequences of human dicer transcripts we
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noticed that it is infested with many upstream open reading
frames (uORF) and out of frame AUG codons [16]. To evalu-
ate whether the 5'-untranslated region of the dicer transcript is
in part responsible for the regulation of the dicer transcripts in
human breast cells we have amplified, cloned and functionally
characterized the 5'-leader sequences of human dicer tran-
scripts from these cells. We report here that the dicer gene in
breast cells is transcribed from a far upstream promoter in
chromosome 14 and the sequence of the 5'-leader sequences
determines the translatability of the dicer transcript and is dic-
tated by alternative splicing of the 5'-exons.
Materials and methods
Cell culture
We used a series of commercially available human lines of
breast cells, including human mammary epithelial (HME) cells
(Clonetics, purchased through Fisher Scientific, Pittsburgh,
PA, USA), MDA-MB-231, MCF-7, MDA-MB-468, MCF-10A,
and BT549. We also used non-breast cells such as HeLa and
HepG2. All cells, other than the HME cells, were purchased
from American Type Culture Collection (ATCC, Manassas,
VA, USA). HMEC cells were grown in medium purchased from
Clonetics under their recommended conditions. Human
breast carcinoma MDA-MD-231 and MDA-MD-468 cells were
maintained in Leibovitz's L-15 medium supplemented with 1%
antibiotic/antimycotic and 10% fetal bovine serum. MCF-10A
cells were maintained in a 1:1 mixture of Ham's F12 medium,
Dulbecco's modified Eagle's medium supplemented with 1%
antibiotic/antimycotic, 0.098 mg/ml cholera toxin, 0.02 µg/µl
epidermal growth factor, 0.5 µg/ml hydrocortisone, and 10%
horse donor heard serum. BT-549 cells were maintained fol-
lowing standard ATCC recommended media. All cells were
maintained in a humidified CO2 (5%) incubator at 37°C. Other
cells were maintained and grown in ATCC recommended
media and conditions [17,18].
5'-RACE
Complementary DNAs (cDNA) were made from total RNA (5
µg) using random primers following standard protocols
[18,19]. The cDNAs were dC-tailed and the 5'-ends of the
dicer mRNAs were amplified using a dicer gene specific
primer (5'-AGTTGACCAAGAACACCG-3'), and the Abridged
Anchor Primer (AAP, Invitrogen, Carlsbad, CA, USA) following
5'-rapid amplification of cDNA ends (RACE) analysis proto-
cols from Invitrogen. Amplicons were re-amplified succes-
sively using nested dicer gene specific primers (5'-
TGACCAAGAACACCGTCC-3', and 5'-AAATGTCTTCCCT-
GAGCC-3'), and AUAP and UAP, respectively. All PCRs were
done using suggested thermocycler conditions of the 5'-
RACE protocol (Invitrogen). 5'-RACE products were cloned in
the pCRII-Topo vector following TOPO-TA cloning protocols
(Invitrogen) and the nucleotide sequences of the cloned
inserts were determined by automated DNA sequencing [19].
S1-nuclease protection assay
Oligonucleotides that were biotinylated at the 5'-end (5'-
CACAGCATGCCCAAGCTT CTGCTCTCAAAATGCTGAT-
TCTAAGTTC-3', and 5'-GCATTTTTGTTCTAGCACAGC
TTACCTTCCCACTCGCCTGCGTTTC-3') spanning the
exon 2 and exon 3 boundary of the long 5'-variant and the exon
1 and exon 4 boundary of the short 5'-variant of the dicer
mRNA, respectively, were custom synthesized and gel-purified
(Invitrogen). The standard S1-nuclease protection protocol
was followed [19] with the following modifications: total cellu-
lar RNA (10 µg) was co-precipitated with each probe (10
pmol) and hybridized at 65°C for 15 h. S1-nuclease (Promega,
Madison, WI, USA) was used at a concentration of 500 units/
ml for 90 min at 37°C. Products were analyzed in a 15% TBE-
urea gel, electrophoretically transferred to Zeta Probe blotting
membrane (BioRad, Hercules, CA. USA) and biotinylated pro-
tected probes were detected using the North2South HRP
Detection protocol (Pierce, Rockford, IL, USA).
5'Leader sequence/Renilla luciferase constructs
The long and short form dicer 5'-leader sequences were ampli-
fied using the forward primer 5'-GCGGAAGTGGGTGTTT-
GTTATTTCC-3' and the reverse primer 5'-
GGATCATAAACTTTCGAAGTCATTGCATTTTTGTTCTAG-
CACAGC-3'. Gene splicing by overlapping extension (SOE)
was used to fuse dicer variants to Renilla luciferase that was
amplified with forward primer 5'-
GCTGTGCTAGAACAAAAATGCAATGACTTCGAAAGTT-
TATGATCC-3' and reverse primer 5'-CTCGAAGCG-
GCCGCTCTAG-3' [20]. The Renilla  luciferase ORF alone
was amplified using forward primer 5'-ATGACTTCGAAAGTT-
TATGATCC-3' and reverse primer 5'-CTCGAAGCG-
GCCGCTCTAG-3'. SOEing products were then ligated into
the pCRII-Topo vector (Invitrogen), digested with EcoRI
(Promega) and cloned at the EcoRI site of pcDNA3.1(+) (Inv-
itrogen) and sequenced with T7 primer to determine the orien-
tation of the cloned insert. It is anticipated from the vector
information (Invitrogen) that the Renilla luciferase transcript
from these constructs will have a 133 nucleotide vector
derived sequence before the 5'-leader sequences from the
dicer gene at their 5'-end. Thus, the nucleotide sequence that
is common to the control and the experimental transcripts is 5'-
TAGAGAACCCACTGCTTACTGGCTTATCGAAAT-
TAATACGACTCACTATAGGGAGACCCAAGCT-
GGCTAGCGTTTAAACTTAAGCTTGGTACCGAGCTCGG
ATCCACTAGTCCAGTGTGGTGGAATTCGGCTT-3'. This
sequence does not have any ATG codon.
Transfection and luciferase assay
Cells were seeded at 80% confluency in a 24-well plate for 24
h in their growth media before co-transfection with one of the
pcDNA3.1(+) test plasmid constructs and pGL3-control plas-
mid. The latter was used as a transfection normalization con-
trol. Plasmids were mixed at 0.5 µg per well and transfection
was done using the Lipofectamine Plus transfection reagentsAvailable online http://breast-cancer-research.com/content/7/4/R563
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(Invitrogen) using the protocol suggested by the supplier.
After 20 h of incubation in complete medium at 37°C, the cells
were lysed in 100 µl passive lysis buffer (Promega) and 5–20
µl of the lysate was assayed [18] for firefly luciferase as well
as Renilla  luciferase activities using Dual Luciferase Assay
Reagents (Promega) following suggested protocols [18].
Renilla luciferase activity was normalized with respect to firefly
luciferase activity and presented as a ratio (relative light units).
Protein contents of the extract, when needed, were deter-
mined using RC-DC reagents and protocol from BioRad Lab-
oratories Hercules, CA, USA [18].
In vitro transcription and translation
The pcDNA3.1(+) constructs containing the cloned inserts
also have a T7 RNA polymerase promoter (Invitrogen). To eval-
uate whether there is any effect of the dicer 5'-leader
sequence insert at the EcoRI site in proper orientation on the
translatability of the mRNA, we used the T7 RNA polymerase/
rabbit reticulocyte lysate in vitro transcription/translation sys-
tem (TNT, Promega). Each plasmid DNA (1 µg) was added to
40 µl of TNT Quick Master Mix containing 1 mM of methionine
(Promega). The reactions were incubated at 30°C for 75 min
then cooled to 4°C. The TNT reactions were diluted 1:2 with
1x passive lysis buffer (Promega) and incubated at room tem-
perature for 15 min. An aliquot (5–20 µl) was assayed in 100
µl of Renilla Luciferase Assay Substrate (Promega).
Statistical procedures
Each data set is presented as mean ± SEM (N = 12). Statisti-
cal significance of a difference between two series of data was
tested by determining the P value [21]. If the P value was less
than 0.05, the difference was considered to be significant
[21].
Results and discussion
Dicer mRNA has a new exon at the 5'-end
The expression of the dicer gene is differentially regulated in
many organisms that have the RNAi mechanism [22-26]. In
humans the expression of this gene is highly tissue specific
[16] and the mechanisms that regulate it are not known. Initial
characterization of dicer mRNA indicated an abundance of
overlapping and non-overlapping uORFs at the 5'-leader
sequences [16]. To evaluate whether the 5'-leader sequences
of dicer mRNA may be a regulatory factor for dicer gene
expression, we amplified, cloned and characterized the 5'-
leader sequences of these mRNAs from human breast cells.
We found that dicer mRNAs have at least two major 5'-leader
sequences (Figs 1, 2, 3). Fig. 1 shows our 5'-RACE data from
MDA-MB-231 and MDA-MB-468 cells. Similar experiments
were done with BT549, MCF7, MCF10A and HMEC cells
with similar results (not shown). In fact, we also found these
two major forms in HepG2 and HeLa cells (data not shown).
We purified the PCR products as a whole and cloned all the
DNA molecules. Nucleotide sequencing of more than 40
clones revealed only two types of sequences from dicer
Figure 1
Ethidium bromide stained agarose gel showing the analysis of the 5'- RACE products from human dicer mRNAs from breast cells Ethidium bromide stained agarose gel showing the analysis of the 5'-
RACE products from human dicer mRNAs from breast cells. Lane M, 1 
kb plus DNA ladder (Invitrogen); lane 1, cDNA from MDA-MB-231; lane 
2, cDNA from MDA-MB-468. The band at approximately 550 bp is for 
the unspliced long form of the 5'-leader sequence. The band at approx-
imately 380 bp is the short spliced form.
Figure 2
Nucleotide sequences of the (a) long form and (b) short form of the 5'- leaders derived from the 5'-RACE products (Entrez Accession numbers  AY845867 and AY845868) Nucleotide sequences of the (a) long form and (b) short form of the 5'-
leaders derived from the 5'-RACE products (Entrez Accession numbers 
AY845867 and AY845868). The exon junctions are indicated by two 
vertical lines. The upstream AUGs and corresponding stop codons are 
numbered and underscored. The AUG at the 3'-end is the putative start 
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mRNAs (Fig. 2). The other bands in the 5'-RACE products
were thus PCR artifacts deriving from mis-priming. The 5'-
leader sequences in the characterized dicer mRNAs are
termed 'long' (320 nucleotides) and 'short' (149 nucleotides)
forms because of their lengths. The human dicer gene was
originally cloned from HepG2 cells and was shown to be
located on chromosome 14q31 near marker D14S605 [16].
The gene was reported to have 28 exons and 27 introns [16].
Our characterization of the 5'-leader sequences of the dicer
mRNA variants from breast cells indicate a new exon at the 5'-
end and 30 extra nucleotides added to the original first exon
(Figs 1, 2, 3). Alignment of the nucleotide sequence to the
chromosome 14 sequence shows that the new exon is tran-
scribed from a segment of the chromosome approximately 16
kb upstream of the transcription start site previously predicted
for human dicer mRNA. Because we have not done extensive
studies with different non-breast cell types, we cannot say at
this point that the transcript originally reported for HepG2 or
other types of cells does not exist. It is possible that human
dicer gene is transcribed from different promoters in different
tissues. Selection of this alternative promoter in breast cells
leads to the formation of a new intron 1 that is 16,184 base
pairs in length (Fig. 3). Alternative promoter selection is a
known mode of regulation of the expression of mammalian
genes [27-29].
The long form of the 5'-leader sequences contains nine
upstream AUG codons (Fig. 2). The short form of the 5'-leader
sequence is the alternatively spliced form of the long form. In
the short form exon 1 is directly joined to exon 4 and exons 2
and 3 are spliced out (Figs 2 and 3); the number of upstream
AUG codons is decreased to five due to this alternative splic-
ing (Fig. 2). Upstream AUG codons often are reported to slow
down the rate of translation of an mRNA [30-37]. We tested
whether the decrease in the upstream AUGs has any effect on
the translatability of the dicer mRNAs (see below).
To ensure that the existence of the different 5'-leader
sequences in dicer mRNA as revealed by the 5'-RACE analy-
sis was not a PCR artifact, and also to determine relative quan-
tities of each of the mRNA isoforms, we verified the levels of
each of the isoforms by S1-nuclease protection assays (Fig.
4). Data from RNAs isolated from MCF-10A, MDA-MB-231,
MDA-MB-468 and BT-549 cells are shown in Fig. 4. We used
beta-actin RNA level as a loading control. Both the short and
long 5'-leader sequence variants were found in these breast
cell lines (not shown). The relative amounts of the two forms
vary from cell to cell, indicating that alternative splicing of dicer
pre-mRNA could be a form of regulation of dicer gene
expression.
Translation of the short 5'-leader form of the dicer mRNA 
is more efficient
To evaluate whether the altered length of the 5'-leader
sequences has any effect on the ability of the mRNA to be
translated we tested reporter gene expression from constructs
that had either the short or the long 5'-leader sequence (Fig.
5). The data shown are with the control constructs, which have
no added 5'-leader sequence. We also performed additional
experiments with constructs that have other unrelated DNA
segments of similar lengths. We found no significant differ-
ences between these controls (data not shown). Transient
Figure 3
Cartoon showing the possible splicing of the 5'-exons of the human  dicer pre-mRNA to produce the short and long forms of mRNAs Cartoon showing the possible splicing of the 5'-exons of the human 
dicer pre-mRNA to produce the short and long forms of mRNAs.
Figure 4
S1-Nuclease protection analysis to verify the long and short forms of  dicer mRNA S1-Nuclease protection analysis to verify the long and short forms of 
dicer mRNA. Autoradiograms showing the relative quantities of (a) 
short from, (b) long form and (c) β -actin mRNAs. See text for details. 
Lanes from left to right: RNA from MCF-10A cells; RNA from MDA-MB-
231 cells; RNA from MDA-MB-468 cells; RNA from BT-549 cells; 50% 
of the probe input; and biotinylated oligonucleotide ladder. The lower 
band in the long form second and third lane from left may be the 3'-trun-
cated (2 nt) form of the biotinylated probe due to the possible degrada-
tion of the fraying 3'-end of probe by S1 nuclease.Available online http://breast-cancer-research.com/content/7/4/R563
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transfection of the breast or non-breast cells with the plasmid
constructs was supposed to produce Renilla  luciferase
mRNAs with the general structure shown in Fig. 5. We lysed
the transfected cells after 20 h and assayed for Renilla luci-
ferase activity in the cell lysate. The plasmid that constitutively
expresses firefly luciferase from SV40 late promoter was used
as transfection control and the Renilla luciferase data were
normalized with respect to the firefly luciferase activity in the
extract. Tthe construct with the long form of the 5'-leader
sequence expressed no significant Renilla luciferase activity
compared to the controls (Fig. 6) in all the cells tested. On the
other hand, the construct with the short form of the 5'-leader
sequence expressed significant Renilla luciferase activity (Fig.
6). The activity from the construct with the short form of the 5'-
leader sequence was much less than from the constructs with
no added 5'-leader sequence, indicating that the residual AUG
codons in the short form of the 5'-leader sequence may still be
negatively regulating the translation and/or stability of the
mRNA. To verify whether inclusion of different 5'-leader
sequences in the reporter plasmid has any effect on the level
of Renilla luciferase mRNA, we performed RT-PCR analysis.
Our data suggest that irrespective of whether the construct
Figure 5
The map of the putative luciferase mRNA synthesized from the plasmid inside the transfected cells The map of the putative luciferase mRNA synthesized from the plasmid inside the transfected cells. The 5'-end 133 nt come from the vector. The 
lengths of the dicer 5'-leader sequence vary. The control does not have any insert. The 3'-untranslated region also comes from the vector. Nt, nucle-
otides; UTR, untranslated region.
Figure 6
Effect of dicer 5'-leader sequences upstream of the luciferase coding sequence on the expression of relative luciferase activities in BT549, MDA- MB-468, HeLa and HepG2 cells Effect of dicer 5'-leader sequences upstream of the luciferase coding sequence on the expression of relative luciferase activities in BT549, MDA-
MB-468, HeLa and HepG2 cells. Luciferase activity is expressed as relative light units (RLU) after normalization with firefly luciferase activity. Results 
are means of data from 12 different experiments ± standard errors. The differences were statistically significant (p < 0.001). UTR, untranslated 
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expresses luciferase activity, there is no significant difference
in the luciferase mRNA levels (Fig. 7). The effect of the added
5'-leader sequences thus may be at the translational level. We
further verified this by in vitro transcription/translation with the
plasmid constructs followed by reporter gene expression anal-
ysis (Fig. 8). This experiment also suggests that perhaps the
consequence of altering the 5'-leader sequence of human
dicer transcripts is the altered translation of the mRNA into
dicer protein. Taken together, these observations imply that
alternative promoter use and alternative splicing of 5'-exons
are important for the regulation of human dicer gene
expression.
Conclusion
In human breast cells, the dicer gene is transcribed from a pro-
moter that is more than 16 kbp upstream of the initiation site
reported for this gene from non-breast cells [16]. This alterna-
tive promoter selection modifies the length and composition of
the 5'-leader sequences of its mRNA. Furthermore, alternative
splicing of the exon 2 and 3 sequences of its pre-mRNA cre-
ates a more translationally competent mRNA in these cells.
Breast cell dicer mRNAs have a high number of upstream
AUG codons with in frame stop codons. Translational effi-
ciency and/or stability of the RNA are decreased due to this
type of 5'-leader sequence [34-37]. The non-sense mediated
degradation pathway of mRNA decay may also be stimulated
by these uORFs [38,39]. It is interesting to note that there is
an association between active dicer mRNA expression and the
invasiveness of the breast cell line. Recently we found that the
zinc finger repressor protein SLUG may have the determina-
tive role in the invasiveness of the breast cell [40,41]. We are
exploring whether dicer regulates SLUG gene expression in
human breast cells. The mechanisms by which the 5'-leader
sequences of the dicer mRNAs in breast cells regulate the
expression of this gene are yet to be determined.
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Figure 7
Verification of Renilla luciferase mRNA levels by RT-PCR in transfected  BT549 cells Verification of Renilla luciferase mRNA levels by RT-PCR in transfected 
BT549 cells. β -Actin mRNA levels were used as control. Lane M, 1 kb 
plus DNA ladder (Invitrogen; lowest band is 200 bp); lane 1–3, RNA 
isolated from BT549 cells transfected with pcDNA3.1(+), 
pcDNA3.1(+)-short form 5'-leader or pcDNA3.1(+)-long form plasmid 
DNA, respectively.
Figure 8
In vitro transcription and translation of the Renilla luciferase gene from  the plasmid constructs and evaluation of the luciferase activity In vitro transcription and translation of the Renilla luciferase gene from 
the plasmid constructs and evaluation of the luciferase activity. Results 
are means of data from 12 different experiments ± standard errors. The 
differences were statistically significant (p < 0.001). UTR, untranslated 
region.Available online http://breast-cancer-research.com/content/7/4/R563
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